A world-leading researcher in solid electrolytes and sophisticated electron microscopy methods received Oak Ridge National Laboratory’s top science honor today for her work in developing new materials for batteries. The announcement was made during a livestreamed Director’s Awards event hosted by ORNL Director Thomas Zacharia.
ORNL's Larry Baylor and Andrew Lupini have been elected fellows of the American Physical Society.
Matthew Ryder has been named an emerging investigator by the American Chemical Society journal Crystal Growth and Design. The ACS recognized him as “one of an emerging generation of research group leaders for his work on porous materials design.”
A team led by the ORNL has found a rare quantum material in which electrons move in coordinated ways, essentially “dancing.”
A multidisciplinary team of scientists at ORNL has applied a laser-interference structuring, or LIS, technique that makes significant strides toward eliminating the need for hazardous chemicals in corrosion protection for vehicles.
Scientists at ORNL and the University of Tennessee, Knoxville, have found a way to simultaneously increase the strength and ductility of an alloy by introducing tiny precipitates into its matrix and tuning their size and spacing.
As rising global temperatures alter ecosystems worldwide, the need to accurately simulate complex environmental processes under evolving conditions is more urgent than ever.
The Department of Energy’s Office of Science has selected five Oak Ridge National Laboratory scientists for Early Career Research Program awards.
At the Department of Energy’s Oak Ridge National Laboratory, scientists use artificial intelligence, or AI, to accelerate the discovery and development of materials for energy and information technologies.
The Accelerating Therapeutics for Opportunities in Medicine , or ATOM, consortium today announced the U.S. Department of Energy’s Oak Ridge, Argonne and Brookhaven national laboratories are joining the consortium to further develop ATOM’s artificial intelligence, or AI-driven, drug discovery platform.